The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturity Offering priced at 0.75% interest rate and 45% conversion premium PALO...
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity PALO ALTO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) --...
- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice...
PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...
PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...
PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...
BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. BBIO maintains a strong technical profile with a 100% “Buy” Barchart opinion. Revenue is projected to...
/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s prospects.
With one blockbuster product, this biotech is gearing up for more product launches next year.
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...